Tag: Glenmark Pharmaceuticals USA
GENERAL Glenmark Gets US FDA Approval For Fluticasone Propionate Nasal Spray

Glenmark Pharmaceuticals Ltd has received approval from the US Food and Drug Administration (US FDA) for Fluticasone Propionate Nasal Spray USP, 0.05 mg (50 mcg)/spray, strengthening its respiratory portfolio in the US market. The company said its Fluticasone Propionate Nasal Spray is bioequivalent and therapeutically equivalent to Flonase Nasal Spray, 0.05 mg/spray, the reference listed […]

CW Bureau · Aug 20, 2026
GENERAL US FDA Expands Glenmark RYALTRIS Approval To Children Above 6 Years

Glenmark Specialty S A has received approval from the US Food and Drug Administration (US FDA) to expand the use of its allergy treatment RYALTRIS nasal spray for pediatric patients aged 6 to less than 12 years suffering from Seasonal Allergic Rhinitis (SAR). The approval broadens the eligible patient population for the drug in the […]

CW Bureau · Jul 21, 2026